TLXTelix Pharmaceuticals Limited

TLX Stock Price, Valuation & Chart | Telix Pharmaceuticals Limited

Compare

$15.620-1.76 (-10.13%)

At close · 21 Aug 2026, 06:10 am

Sector: Healthcare Industry: Biotechnology TLX intrinsic value Is TLX overvalued or undervalued Website

Overview Financials Dividends Ratios

TLX Historical price chart

TLX Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization5.29B

PE Ratio-563.7

EPS-0.03

Trading Volume4.58M

Today's High/Low16.76/15.62

Dividend Yield0.00

52 Week High/Low19.07/8.26

Shares Outstanding338.78M

TLX Financial Statement

TLX Analyst ratings

Buy

Strong buy

Buy

Hold

Sell

Strong sell

Based on 14 analysts giving stock ratings to TLX in the past 3 months.

TLX Analysis & performance metrics

TLX Company profile

Telix Pharmaceuticals Limited, a radiopharmaceutical company, develops molecularly targeted radiation (MTR) products for cancer and rare diseases in Australia, Belgium,…

Telix Pharmaceuticals Limited, a radiopharmaceutical company, develops molecularly targeted radiation (MTR) products for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company focuses on developing diagnostic and therapeutic products using MTR. Its lead products include TLX591-CDx for the diagnosis and treatment of metastatic…

TLX Management team

Name

Position

Lena Moran-Adams L.L.B.

Group General Counsel

Craig UlrickCTO

Chief Information Officer

Michael Wheatcroft B.Sc., BSc(Hons), Ph.D., Ph.D., (Cantab)

Chief Scientist

Christian P. Behrenbruch BEng(Hons), DPhil(Oxon), GAICD, J.D., M.B.A., MBACEO

Co-Founder, MD, Group Chief Executive Officer & Executive Director

Andreas Kluge M.D., Ph.D.

Chief Medical Advisor

Darren PattiCOO

Group Chief Operating Officer

Richard Valeix M.B.A.CEO

Chief Executive Officer of Telix Therapeutics

Darren Smith B.Bus., FCPA, M.B.A.CFO

Group Chief Financial Officer

Name

Position

Lena Moran-Adams L.L.B.

Group General Counsel

Craig UlrickCTO

Chief Information Officer

Michael Wheatcroft B.Sc., BSc(Hons), Ph.D., Ph.D., (Cantab)

Chief Scientist

Christian P. Behrenbruch BEng(Hons), DPhil(Oxon), GAICD, J.D., M.B.A., MBACEO

Co-Founder, MD, Group Chief Executive Officer & Executive Director

Andreas Kluge M.D., Ph.D.

Chief Medical Advisor

Darren PattiCOO

Group Chief Operating Officer

Richard Valeix M.B.A.CEO

Chief Executive Officer of Telix Therapeutics

Darren Smith B.Bus., FCPA, M.B.A.CFO

Group Chief Financial Officer

Management Team

Lena Moran-Adams L.L.B.

Group General Counsel

Craig UlrickCTO

Chief Information Officer

Michael Wheatcroft B.Sc., BSc(Hons), Ph.D., Ph.D., (Cantab)

Chief Scientist

Christian P. Behrenbruch BEng(Hons), DPhil(Oxon), GAICD, J.D., M.B.A., MBACEO

Co-Founder, MD, Group Chief Executive Officer & Executive Director

Andreas Kluge M.D., Ph.D.

Chief Medical Advisor

Darren PattiCOO

Group Chief Operating Officer

Richard Valeix M.B.A.CEO

Chief Executive Officer of Telix Therapeutics

Darren Smith B.Bus., FCPA, M.B.A.CFO

Group Chief Financial Officer

Management

Lena Moran-Adams L.L.B.

Group General Counsel

Craig UlrickCTO

Chief Information Officer

Michael Wheatcroft B.Sc., BSc(Hons), Ph.D., Ph.D., (Cantab)

Chief Scientist

Christian P. Behrenbruch BEng(Hons), DPhil(Oxon), GAICD, J.D., M.B.A., MBACEO

Co-Founder, MD, Group Chief Executive Officer & Executive Director

Andreas Kluge M.D., Ph.D.

Chief Medical Advisor

Darren PattiCOO

Group Chief Operating Officer

Richard Valeix M.B.A.CEO

Chief Executive Officer of Telix Therapeutics

Darren Smith B.Bus., FCPA, M.B.A.CFO

Group Chief Financial Officer

Total 8 executives

TLX Frequently asked questions

What is Telix Pharmaceuticals Limited (TLX) Stock Price?

Current stock price of Telix Pharmaceuticals Limited (TLX) stock is $15.620. The stock price is -10.13% lower in the session. The intraday range can be seen from this page. Volume of Telix Pharmaceuticals Limited (TLX) stock is 4.58M.

Last updated at 21 Aug 2026, 06:10 am.

Why is the Telix Pharmaceuticals Limited (TLX) stock price going up or down today?

The stock price of Telix Pharmaceuticals Limited (TLX) can change with earnings, company news, and overall market sentiment. Telix Pharmaceuticals Limited operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Telix Pharmaceuticals Limited stock expensive at its current price?

Whether Telix Pharmaceuticals Limited looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for TLX on this page is -563.70. EPS on this page is -0.03. Compare those figures with peers and growth expectations before deciding if the current Telix Pharmaceuticals Limited price is justified.

How has the stock price of Telix Pharmaceuticals Limited (TLX) performed historically?

Historical performance for Telix Pharmaceuticals Limited (TLX) is shown on the price chart on this page. Review multi-period moves alongside volume to see how TLX reacted to past earnings and market events.

Should I buy Telix Pharmaceuticals Limited (TLX) stock, at this price?

Buying Telix Pharmaceuticals Limited (TLX) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.